Stelara denied by insurance? How to appeal
The short answer
Many plans now prefer a biosimilar version of ustekinumab, the medicine in Stelara, and deny the brand. If you can switch, ask your doctor to prescribe the plan's preferred version. If you cannot, ask for a formulary exception with records showing why. If the denial says you did not meet the medical criteria, an appeal with your treatment history is worth filing.
- StartThe denial letterFind what was denied, the reason, and the deadline to appeal.
- Step 1Appeal to your planMost plans give you 60 to 180 days to ask. The plan reviews its own decision.
- Step 2Go outside the planIf it says no again, someone outside the plan can decide: an independent reviewer, a hearing, or a federal office.
Can’t wait? If waiting could seriously harm your health, ask for a fast appeal. Most plans must decide within 72 hours.
What Stelara is approved for
Stelara (ustekinumab) blocks interleukin-12 and -23. As of November 2026 its FDA label lists four uses:
- Moderate to severe plaque psoriasis in adults and children 6 and older who are candidates for light therapy or systemic therapy.
- Active psoriatic arthritis in adults and children 6 and older.
- Moderately to severely active Crohn's disease in adults and children 2 and older.
- Moderately to severely active ulcerative colitis in adults and children 2 and older.
Biosimilars include Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana and Yesintek, among others listed in one insurer’s policy.
Why plans deny Stelara
The plan prefers a biosimilar. One insurer's October 2026 policy says Stelara requires the use of preferred ustekinumab products before non-preferred ones are approved. Its national formulary program requires trials of preferred products when clinically appropriate, and its tables list Imuldosa, Selarsdi, ustekinumab-ttwe and Yesintek as the preferred ustekinumab products, not brand Stelara.
Prior-authorization criteria were not met. Initial approval generally requires a specialist prescriber. For Crohn's disease, that policy asks for a gastroenterologist and an IV induction dose within 2 months of starting the injections.
The renewal lacked proof of response. Plans often reapprove only with records showing the drug is working.
Note that the same policy says a trial of several ustekinumab products counts as one product when a plan asks you to try other drug classes.
Reading the denial
Job-based plans must name the specific plan provision behind a denial, and you can ask for a free copy of the criteria. "Criteria not met" means the plan wanted more medical proof; see prior authorization denials. "Step therapy" or "try a preferred product first" means the plan wants another drug tried; see step therapy denials. "Non-formulary" means Stelara is not on the drug list, which calls for a formulary exception. Check your plan's drug list to see what it prefers.
What your doctor's letter should document
Ask for a letter of medical necessity that answers each criterion, in order, with dated records:
- The diagnosis, its diagnosis code, and how active the disease is, with scope, lab or skin measurements.
- Every prior treatment with doses, dates and results.
- If asking for brand Stelara: each biosimilar tried, the dates, and the specific reaction or failure.
- The specialist's role.
- For renewals, measurements from before treatment and now.
Ask the plan for the written criteria it used. Job-based plans must name the specific plan provision behind a denial and give you a free copy of any criteria they relied on. File the internal appeal within 180 days of the denial.
If Stelara is not on the drug list, ask for a formulary exception instead of, or alongside, the appeal. Your doctor generally confirms that covered drugs have not worked, will not work as well, or are likely to cause harm. Individual and small-group plans must decide a standard request within 72 hours and an expedited one within 24 hours, and a denial can go to an independent reviewer. See formulary exception letters.
If the plan upholds a denial that turned on medical judgment, you can ask for external review within 4 months of the final decision. Your insurer has to accept the reviewer’s decision.
Medicare, Medicaid and manufacturer help
With a Medicare drug plan, ask for a coverage determination or exception. Your prescriber must provide a statement explaining the medical reason. The plan must decide within 72 hours, or 24 hours if expedited, and Part D exceptions can also cover step therapy and dose limits. You have 65 days to appeal a denial. See Part D appeals.
When a clinic gives the drug, Medicare may pay under Part B instead. Medicare.gov says Part B usually covers drugs you wouldn’t typically give to yourself, like those given in a doctor's office, and most injectable and infused drugs when a licensed provider gives them. Ask the clinic which part of Medicare it is billing, because the appeal path differs. See Original Medicare appeals.
State Medicaid programs may require prior authorization for any covered drug. See Medicaid appeals.
Questions people ask
Why won't my insurance cover Stelara anymore?
Often because the plan now prefers a biosimilar. One insurer requires preferred ustekinumab products before brand Stelara. Ask your doctor whether the preferred version is right for you.
Can I get an exception to stay on brand Stelara?
You can ask. Your doctor documents why the preferred versions will not work, such as a reaction you had on one, with dates. See formulary exception letters.
Insurance stopped covering Stelara after I'd been on it. What can I do?
First find out why: a lapsed prior authorization, a renewal that asked for proof the drug is working, or a drug-list change. Ask your doctor to resubmit with current records. In individual and small-group plans, being in the middle of a course of treatment on a non-formulary drug qualifies for a 24-hour expedited exception. Medicare drug plans must offer a temporary supply in the first 90 days under a new plan, and that process also covers current enrollees affected by formulary changes.
What if my Stelara appeal is denied?
If the denial turned on medical judgment, you can ask for external review by an independent reviewer within 4 months of the plan's final decision. A denied formulary exception in an individual or small-group plan can also go to independent review. With Medicare Part D, if the plan upholds its denial you have 60 days to ask a Part D Independent Review Entity to reconsider; see Part D appeals.
Sources
- National Library of Medicine (DailyMed): STELARA (ustekinumab) prescribing information (DailyMed)
STELARA is a human interleukin-12 and -23 antagonist indicated for the treatment of
- Cigna Healthcare: Drug Coverage Policy IP0687: Ustekinumab Subcutaneous Prior Authorization Policy (effective 10/01/2026)
This product also requires the use of preferred ustekinumab subcutaneous products before approval of non-preferred ustekinumab subcutaneous products.
- Cigna Healthcare: Inflammatory Conditions Preferred Specialty Management Policy for National Preferred and Basic Formularies (Cigna, review date 07/29/2026)
this program requires trial(s) of the Preferred Product(s) according to the table below when clinically appropriate, prior to the approval of the Non-Preferred Products
- eCFR (Office of the Federal Register): 29 CFR 2560.503-1 -- Claims procedure
Reference to the specific plan provisions on which the determination is based
- HealthCare.gov: Getting prescription medications
Visit your insurer’s website to review a list of prescriptions your plan covers
- HealthCare.gov: Internal appeals
You must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied.
- eCFR (Office of the Federal Register): 45 CFR 156.122 -- Prescription drug benefits
A health plan must make its determination on a standard exception and notify the enrollee or the enrollee's designee and the prescribing physician (or other prescriber, as appropriate) of its coverage determination no later than 72 hours following receipt of the request.
- HealthCare.gov: External Review
You must file a written request for an external review within 4 months after the date you receive a notice or final determination from your insurer that your claim has been denied.
- Medicare.gov: Appeals in a Medicare drug plan
If you're asking for an exception, your prescriber must provide a statement explaining the medical reason why the exception should be approved.
- eCFR (Office of the Federal Register): 42 CFR 423.568 -- Standard timeframe and notice requirements for coverage determinations
but no later than 72 hours after receipt of the physician's or other prescriber's supporting statement
- eCFR (Office of the Federal Register): 42 CFR 423.572 -- Timeframes and notice requirements for expedited coverage determinations
but no later than 24 hours after receipt of the physician's or other prescriber's supporting statement
- eCFR (Office of the Federal Register): 42 CFR 423.578 -- Exceptions process
An exception to a plan's coverage policy that causes a Part D prescription drug not to be covered because of cost utilization tools, such as a requirement for step therapy, dosage limitations, or therapeutic substitution.
- Legal Information Institute, Cornell Law School: 42 U.S. Code § 1396r-8 - Payment for covered outpatient drugs
A State may subject to prior authorization any covered outpatient drug
- Medicare.gov: Prescription drugs (outpatient)
Usually, Part B covers drugs you wouldn't typically give to yourself, like those you get at a doctor's office or in a hospital outpatient setting.
- eCFR (Office of the Federal Register): 42 CFR 423.120 -- Access to covered Part D drugs
Ensure access to a temporary supply of drugs within the first 90 days of coverage under a new plan.
This page is general information about appeal rules in the United States. It is not legal or medical advice. Rules can change, and your plan’s documents and your denial letter control the dates that apply to you.